[1] Agarwal JP, Nemade B, Murthy V, et al. Hypofractionated, palliative radiotherapy for advanced head and neck cancer [J]. Radiother Oncol, 2008, 89(1): 51-56. [2] Das S, Thomas S, Pal SK, et al. Hypofractionated palliative radiotherapy in locally advanced inoperable head and neck cancer: CMC Vellore experience [J]. Indian J Palliat Care, 2013, 19(2): 93-98. [3] Agrawal A, Purandare N, Shah S, et al. Response assessment in metronomic chemotherapy: RECIST or PERCIST ? [J].Indian J Nucl Med, 2014, 29(2): 74-80. [4] Gomez-Roca C, Koscielny S, Ribrag V, et al. Tumour growth rates and RECIST criteria in early drug development [J]. Eur J Cancer, 2011, 47(17): 2512-2516. [5] Denis F, Garaud P, Bardet E, et al. Late toxicity results of the GORTEC 94-01 randomized trial comparing radiotherapy with concomitant radiochemotherapy for advanced-stage oropharynx carcinoma: comparison ofLENT/SOMA, RTOG/EORTC, and NCI-CTC scoring systems[J]. Int J Radiat Oncol Biol Phys, 2003, 55(1): 93-98. [6] Bhargava D, Deshpande A, Sreekumar K , et al. Guidelines of the infectious diseases society of America for the treatment of methicillin-resistnat Staphylococcus aureus infections: as applied to oral and maxillofacial clinical practice [J]. J Maxillofac Oral Surg, 2013, 12(3): 354-358. [7] Moros EG, Fan X, Straube WL, et al. Numerical and in vitro evaluation of temperature fluctuations during reflected-scanned planar ultrasound hyperthermia [J]. Int J Hyperthermia, 2009, 14(4):367-382. [8] 翟亮, 孙福成, 蒋继伟, 等. 超声热疗技术的发展与应用 [J]. 中国医疗器械杂志, 2002, 26(4): 281-283. [9] Pantazis P, Han Z, Wyche J, et al. Schedule-dependent efficiency of thermochemotherapy in vitro with etoposide and heating at 43 degrees C[J]. Anticancer Res, 1999, 19(2A): 995-998. [10] Stein U, Jurchon K, Walther W, et al. Hyperthermia-induced nuclear translocation of transcription factor YB-1 leads to enhanced expression of multidrug resistance-related ABC transporters [J]. J Biol Chem, 2003, 276(30): 28562-28569. [11] Mohamed F, Marchettini P, Stuart OA, et a1.Thermal enhancement of new chemotherapeutic agents at moderate hyperthermia [J]. Ann Surg Oncol, 2004, 10(4): 463-468. [12] 王升志, 何永文, 毛祖彝, 等. 高温诱导BcaCD885颊癌细胞凋亡及检测 [J].口腔颌面外科杂志, 2000, 10(3): 239-242. [13] Shimura T, Kitagawa M, Yamada T, et al. The impact of cross-resistance between paclitaxel and docetaxel for metastatic gastric cancer [J]. Onkologie, 2012, 35(4): 176-183. [14] AI-Batran SE, Ajani JA. Impact of chemotherapy on quality of life in patients with metastatic esophagogastric cancer [J]. Cancer, 2010, 116(11): 2511-2518. [15] Pignon JP, le Maître A, Maillard E, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients[J].Radiother Oncol, 2009,92(1):4-14. [16] 羊一飞, 郭伟, 邱蔚六, 等. 超声热疗联合顺铂治疗口腔鳞癌裸鼠移植瘤的实验研究 [J]. 中国口腔颌面外科杂志, 2003, 1(4): 228-232. [17] 孟箭, 郭伟. 人舌鳞癌裸鼠原位移植模型的建立及其应用价值 [J]. 中国肿瘤, 2000, 9(10): 478-479. [18] Ressel A, Schmitt O, Weiss C, et al. Therapeutic outcome and side-effects after radiotherapy. chemotherapy and /or hyperthermia treatment of head and neck tumour xenograft [J]. Eur J Cancer, 2002, 38(4): 594-601. [19] Hoshina H, Takagi R, Tsurumaki H, et al. Clinical result of thermochemoradiotherapy for advanced head and neck cancer [J]. Gan to Kagaku Ryoho, 2001, 28(3): 331-336. |